All In Biotech

NDA 215256 · Novo

Wegovy

Semaglutide · Subcutaneous

NovelBreakthrough therapyAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 4, 2021

Approved uses

8

Original approval plus efficacy supplements

Registered trials

626

187 Phase 3, 161 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )] . • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...

What it is approved for

From the label in effect Apr 23, 2024.

WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (1) . • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition (1) . Limitations of Use: • Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended (1).

Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake. The exact mechanism of cardiovascular risk reduction has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 19, 2026 Supplement 29 · Efficacy LetterLabelMedication Guide
  • Nov 21, 2025 Supplement 23 · Efficacy LetterLabel
  • Aug 15, 2025 Supplement 24 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Nov 27, 2024 Supplement 15 · Efficacy LetterLabel
  • Mar 8, 2024 Supplement 11 · Efficacy · priority review LabelLetterReview
  • Jul 21, 2023 Supplement 7 · Efficacy LetterLabel
  • Dec 23, 2022 Supplement 5 · Efficacy · priority review LabelLetter
  • Jun 4, 2021 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelAccelerated approvalLabelLetterReview
12 products under this application
  • WEGOVY · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 2.4MG/0.75ML (2.4MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 2.4MG/0.75ML (2.4MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY HD · SEMAGLUTIDE 7.2MG/0.75ML (7.2MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY FLEXTOUCH · SEMAGLUTIDE 9.6MG/3ML (3.2MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 1.7MG/0.75ML (1.7MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 1.7MG/0.75ML (1.7MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WEGOVY · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.

All 626 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Wegovy (Semaglutide)

2024 spending

$301M

Beneficiaries

52,961

211,575 claims

Per beneficiary

$5,689

$602.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$199,774
2024$301,283,291

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 782 on PubMed

Sponsor: Novo · Also marketed as Wegovy Hd, Wegovy Flextouch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.